Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nicotine,Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CVSI-007 contains nicotine and cannabidiol which supports the cessation of smokeless tobacco use and addiction, if approved it'll be the first and only treatment for smokeless tobacco addiction.
Brand Name : CVSI-007
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 23, 2023
Lead Product(s) : Nicotine,Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CV Sciences and University of California Publish Study of Cannabidiol Efficacy
Details : In this study, rats dependent on nicotine and experiencing withdrawals were treated with CBD. Treatment prevented the animals from exhibiting withdrawal symptoms – including increased pain sensitivity and weight gain – during short- and long-term nic...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 20, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?